880
Participants
Start Date
March 31, 2012
Primary Completion Date
May 31, 2016
Study Completion Date
May 31, 2016
Modification of Prasugrel based on a biological assay
Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
prasugrel / clopidogrel
fixed dose of prasugrel 5 mg
Verify Now
Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
CHU Caremeau à Nimes - Service de Cardiologie, Nîmes
ACTION study group - Institut de Cardiologie- Hôpital la Pitié Salpêtrière, Paris
Collaborators (2)
Eli Lilly and Company
INDUSTRY
Daiichi Sankyo
INDUSTRY
Allies in Cardiovascular Trials Initiatives and Organized
OTHER
Accumetrics, Inc.
INDUSTRY
Stentys
INDUSTRY
Assistance Publique - Hôpitaux de Paris
OTHER